Fiscal Year (FY) 2027 Service Area Competition (SAC) vs Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
Side-by-side comparison of two grants.
| Attribute | Fiscal Year (FY) 2027 Service Area Competition (SAC) | Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required) |
|---|---|---|
| Type | Grant | Grant |
| Funding amount | $10.1M | — |
| Deadline | Closes today | Closes 2026-11-19 |
| Region | US | US |
| Sector | Health | Health |
| Funder | Health Resources and Services Administration | National Institutes of Health |
| Who it's for | nonprofits | individuals, researchers, students, government |
noindex — no measured search demand